Skip to content
PHP BiotechHope for Life

Chief Operating Officer · Physician-executive

Eduardo Motti, MD

Chief Operating Officer

Five hundred trials, then a nanobody

Physician-executive with more than 30 years across academic medicine, Merck, Pfizer, Bayer, and 500+ clinical research projects. Co-author of the peer-reviewed 3-NAntC paper.

clinical research projects
500+
M.D., University of São Paulo
1978
GFMD, IFAPP Academy inaugural cohort
2020

Clinical research turned extractive when scale replaced local expertise. PHP53-nb will need the opposite: sites and patients treated as partners, not throughput.

Argument developed in his 2024 Clinical Leader column

The job at PHP is a protocol, not a press release

Motti’s task is to turn a peptide-and-nanobody story into a clinical development plan that a regulator can read without wincing: endpoints, geographies, ethics, and the unfashionable work of making a first-in-human study actually enroll. He has run that machine inside Merck, Pfizer, and Bayer, and later as an independent designer of trials.

Why he is on the 3-NAntC paper

He is not a guest name. The 2024 Molecules paper lists Bezerra and Motti, both at PHP Biotech International Inc. in Keller, Texas, with company funding disclosed. That is how a COO who still writes about trial ethics also stands behind the peptide that PHP53-nb carries.

Industry path

  1. 1978

    M.D.

    University of São Paulo Medical School

  2. 1988

    Infectious-disease residency and mastership

    USP

  3. 1984–2001

    Pharmaceutical development

    Merck Sharp & Dohme (17 years)

  4. 2000s

    Clinical operations leadership

    Eurotrials · Schering AG / Bayer · Pfizer LATAM · Aché

  5. 2012

    Founder

    Trials & Training

  6. 2013

    Executive coaching certification

    Royal Roads University

  7. Now

    Chief Operating Officer

    PHP Biotech

From the wards to 500 trials

Dr. Eduardo Motti serves as Chief Operating Officer of PHP Biotech and is one of the company’s most credentialed drug-development leaders, with more than 30 years spanning academic medicine, the global pharmaceutical industry, and clinical research operations.

He earned his medical degree from the University of São Paulo Medical School in 1978 and completed a residency and mastership in infectious diseases at USP. After years as a clinician he moved into pharmaceutical development in 1984, beginning a 17-year tenure at Merck Sharp & Dohme. He later held senior roles at Eurotrials, Schering AG (now Bayer), Pfizer — where he served as regional director of clinical operations for Latin America — and Aché Laboratories.

In 2012 he founded Trials & Training, a consultancy supporting biopharmaceutical companies on clinical trial design and medical strategy. Across his career he has contributed to more than 500 clinical research projects. In 2020 he was named a Global Fellow in Medicines Development (GFMD) by the IFAPP Academy. At PHP Biotech he translates scientific promise into a disciplined clinical development plan for PHP53-nb. He is a co-author, with Dr. Patrícia Bezerra, of the 2024 Molecules paper describing 3-NAntC.

Independent indexes

Bibliography and appointments

Everything below is meant to be checked. Empty categories are omitted rather than padded.

Appointments and training

  • M.D., University of São Paulo Medical School, 1978
  • Residency and mastership in infectious diseases, University of São Paulo, 1988
  • Executive coaching certification, Royal Roads University, Victoria, B.C., 2013
  • PHP Biotech International Inc. (Chief Operating Officer)
  • Trials & Training (Founder)
  • IFAPP Academy (Global Fellow in Medicines Development)

Awards and memberships

  • Global Fellow in Medicines Development (GFMD), IFAPP Academy, 2020 — inaugural cohort of 117 fellows from 24 countries
  • IFAPP Academy

Independently indexed publications

Indexed on PubMed, Crossref, or Google Patents. Internal, unpublished data is not listed as peer-reviewed work.

  1. Peer-reviewed · 2024

    3-NAntC: A Potent Crotoxin B-Derived Peptide against the Triple-Negative MDA-MB-231 Breast Cancer Cell Line

    Bezerra P, Motti EF

    Molecules. 2024;29(7):1646

    doi:10.3390/molecules29071646PMID 38611925

    Peer-reviewed open access. Authors affiliated with PHP Biotech International Inc.; research funded by the company.

  2. Commentary · 2024

    Is Clinical Research Inclusive Or Extractive?

    Motti EF

    Clinical Leader (guest column)

    Industry commentary on trial inclusivity, 6 December 2024.

  3. Commentary · 2025

    Should We Be Paying Clinical Research Participants? A Global Perspective

    Motti EF

    Clinical Leader (guest column)

    Industry commentary, 4 March 2025.